Personalized vaccine trial aims to boost immune attack on advanced skin cancer
NCT ID NCT05309421
Summary
This study is testing whether adding a personalized cancer vaccine called EVX-01 to standard immunotherapy (pembrolizumab) can better control advanced melanoma. It involves 17 adults whose melanoma has spread or cannot be removed by surgery and who have not yet received this type of immunotherapy. Patients receive the standard drug for about two years, with the personalized vaccine starting at week 12 to try to train their immune system to better recognize and fight their cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Divisione di Oncologia Medica del Melanoma
Milan, Italy
-
Instituto Nazionale Tumori IRCCS Fondazione
Naples, Italy
-
Melanoma Institute Australia
Wollstonecraft, New South Wales, 2065, Australia
-
One Clinical Research
Nedlands, Western Australia, 6009, Australia
Conditions
Explore the condition pages connected to this study.